1. DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. (21st January 2022) Authors: Vermeire, S; Colombel, J F; Takeuchi, K; Gao, X; Panaccione, R; Danese, S; Dubinsky, M; Schreiber, S; Ilo, D; Finney-Hayward, T; Zhou, W; Phillips, C; Yao, X; Zhou, Q; Loftus, E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme. (21st January 2022) Authors: Higgins, P; Colombel, J F; Reguiero, M; Parkes, G; Ilo, D; Philips, C; Yao, X; Cheng, E; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i088 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. (21st January 2022) Authors: Vermeire, S; Danese, S; Zhou, W; Klaff, J; Ilo, D; Yao, X; Levy, G; Higgins, P D R; Loftus, E V; Panaccione, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i090 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results. (30th January 2023) Authors: D'Haens, G; Tran, J; Danese, S; Rubin, D T; Aoyama, N; Lügering, A; Klaff, J; Xuan, S; Ilo, D; Sanchez Gonzalez, Y; Panes, J Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme. (21st January 2022) Authors: Colombel, J F; Cao, Q; Ghosh, S; Reinisch, W; Zhou, W; Ilo, D; Shu, L; Yao, X; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i036 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis. (21st January 2022) Authors: Panaccione, R; Collins, E B; Melmed, G Y; Vermeire, S; Danese, S; Higgins, P D R; Zhou, W; Ilo, D; Sharma, D; Sanchez Gonzalez, Y; Wang, S T Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i037 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance. (21st January 2022) Authors: Panés, J; Loftus, E V J; Higgins, P; Lindsay, J O; Zhou, W; Yao, X; Ilo, D; Phillips, C; Tran, J; Sanchez Gonzalez, Y; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial. (21st January 2022) Authors: Parkes, G; Ungaro, R; Danese, S; Abreu, M; Arenson, E; Zhou, W; Ilo, D; Laroux, F S; Deng, H; Sanchez Gonzalez, Y; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i476 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison. (30th January 2023) Authors: Reinisch, W; Panaccione, R; Duijvestein, M; Ceballos Santos, D; Melmed, G Y; Xuan, S; Wegrzyn, L; Levy, G; Ilo, D; Sanchez Gonzalez, Y Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. (21st January 2022) Authors: Colombel, J F; Panaccione, R; Nakase, H; Burmester, G; Cohen, S B; Mease, P; Guttman-Yassky, E; Liu, J; Zhou, W; Ilo, D; Higgins, P Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗